Methamphetamine-Associated Psychosis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Methamphetamine (METH) is a frequent drug of abuse in U.S. populations and commonly associated with psychosis. This may be a factor in frequent criminal justice referrals and lengthy treatment required by METH users. Persecutory delusions and auditory hallucinations are the most consistent symptoms of METH-associated psychosis (MAP). MAP has largely been studied in Asian populations and risk factors have varied across studies. Duration, frequency and amount of use as well as sexual abuse, family history, other substance use, and co-occurring personality and mood disorders are risk factors for MAP. MAP may be unique with its long duration of psychosis and recurrence without relapse to METH. Seven candidate genes have been identified that may be associated with MAP. Six of these genes are also associated with susceptibility, symptoms, or treatment of schizophrenia and most are linked to glutamatergic neurotransmission. Animal studies of pre-pulse inhibition, attenuation of social interaction, and stereotypy and alterations in locomotion are used to study MAP in rodents. Employing various models, rodent studies have identified neuroanatomical and neurochemical changes associated with METH use. Throughout this review, we identify key gaps in our understanding of MAP and suggest potential directions for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, T. E., & Becker, J. B. (1986) · Brain Research Reviews · doi:10.1016/0165-0173(86)90002-0 · Cited by 1,796
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Ding, Y.-S., Sedler, M., Logan, J., Franceschi, D., Gatley, J., Hitzemann, R., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2015 · Cited by 916 · cited 4×
“However, this pronounced effect persists long after cessation of drug administration (Sekine et al. 2001, 2003; Volkow et al. 2001c; Wilson et al. 1996).”
BackgroundInfluentialMeta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia
Badner, J. A., & Gershon, E. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001012 · Cited by 811 · cited 3×
“been found to be a susceptibility locus for schizophrenia (Badner and Gershon 2002), and many studies have found an association between genetic variants in DAOA and”
BackgroundNew Insights into the Mechanism of Action of Amphetamines
Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105140 · Cited by 731 · cited 1×
“The interested reader is referred to the following reviews on these topics (Cadet and Krasnova 2009; Fleckenstein et al. 2007; Volz et al. 2007).”
BackgroundProkineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus
Cheng, M. Y., Bullock, C. M., Li, C., Lee, A. G., Bermak, J. C., Belluzzi, J., Weaver, D. R., Leslie, F. M., & Zhou, Q.-Y. (2002) · Nature · doi:10.1038/417405a · Cited by 715 · cited 1×
“In the CNS, prokineticin 2 modulates neurogenesis, circadian rhythms, and migration of the subventricular zone-derived neuronal progenitors (Cheng et al. 2002; Ng et al. 2005).”
BackgroundPsychiatric Diagnoses of Treatment-Seeking Cocaine Abusers
Rounsaville, B. J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810250045005 · Cited by 605
Cannabis dependence and psychotic symptoms in young people
FERGUSSON, D. M., HORWOOD, L. J., & SWAIN-CAMPBELL, N. R. (2003) · Psychological Medicine · doi:10.1017/s0033291702006402 · Cited by 415 · cited 2×
“METH, cocaine, cannabis, alcohol, hallucinogens, sedatives, and heroin have all been implicated in substanceinduced psychosis (Caton et al. 2005; van Os et al. 2002; Fergusson et al. 2003; Arseneault et al. 2004; Manschreck et al. 1988).”
BackgroundMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336 · cited 2×
“As evidence is mounting that glutamate hypo-function may be related to the etiology of schizophrenia (Konradi and Heckers 2003), it is postulated that DTNBP1 variants may contribute to MAP”
BackgroundRemoving Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328 · cited 4×
“…validity, attention to continually improving the match between what is measured at the behavioral (psychological) and neural levels in the animal models of MAP with what is believed to be the behavioral and neural processes underlying this psychosis in humans (Markou et al. 2009) is essential.”
BackgroundInfluentialPre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis
CHEN, C.-K., LIN, S.-K., SHAM, P. C., BALL, D., LOH, E.-W., HSIAO, C.-C., CHIANG, Y.-L., REE, S.-C., LEE, C.-H., & MURRAY, R. M. (2003) · Psychological Medicine · doi:10.1017/s0033291703008353 · Cited by 295 · cited 14×
“Other frequently reported symptoms were delusions of reference, visual hallucinations, and thought broadcasting (Chen et al. 2003; Srisurapanont et al. 2003; Akiyama 2006).”
BackgroundInfluential
Cited by
Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review
Paulus, M. P., & Stewart, J. L. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.0246 · Cited by 310
Methamphetamine Psychosis: Epidemiology and Management
Glasner-Edwards, S., & Mooney, L. J. (2014) · CNS Drugs · doi:10.1007/s40263-014-0209-8 · Cited by 266
Effects of single dose intranasal oxytocin on social cognition in schizophrenia
Davis, M. C., Lee, J., Horan, W. P., Clarke, A. D., McGee, M. R., Green, M. F., & Marder, S. R. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.023 · Cited by 124
Clinical management of psychostimulant withdrawal: review of the evidence
Li, M. J., & Shoptaw, S. J. (2023) · Addiction · doi:10.1111/add.16093 · Cited by 39
Self-citationA comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence
Alexander, P. D., Gicas, K. M., Willi, T. S., Kim, C. N., Boyeva, V., Procyshyn, R. M., Smith, G. N., Thornton, A. E., Panenka, W. J., Jones, A. A., et al. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4551-7 · Cited by 29
Metadata
- Authors
- Grant, K. M., LeVan, T. D., Wells, S. M., Li, M., Stoltenberg, S. F., Gendelman, H. E., Carlo, G., & Bevins, R. A.
- Venue
- Journal of Neuroimmune Pharmacology
- Published
- 2011-07-05
- Volume
- 7
- Issue
- 1
- Pages
- 113-139
- ISSN
- 1557-1890 (ISSN-L)
- 1557-1904
- OpenAlex
- W2011633221
- Cited by
- 231
- References
- 13
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methamphetamine-Associated Psychosis. https://app.cochat.ai/papers/10.1007/s11481-011-9288-1
- The paper
- Grant, K. M., LeVan, T. D., Wells, S. M., Li, M., Stoltenberg, S. F., Gendelman, H. E., Carlo, G., & Bevins, R. A. (2012). Methamphetamine-Associated Psychosis. Journal of Neuroimmune Pharmacology. https://doi.org/10.1007/s11481-011-9288-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.